Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012

Urologic Oncology: Seminars and Original Investigations

Volumn 34, Issue 2, 2016, Pages 57.e15-57.e22

  Nezolosky, Michelle D ^a   Dinh, Kathryn T ^b   Muralidhar, Vinayak ^b   Mahal, Brandon A ^b   Chen, Yu Wei ^c   Beard, Clair J ^a,b   Choueiri, Toni K ^b   Martin, Neil E ^a,b   Sweeney, Christopher J ^b   Trinh, Quoc Dien ^b   Nguyen, Paul L ^a,b  

^a Department of Radiation Oncology   (Iran)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical T3 disease; Prostate cancer; Prostatectomy; Radiation therapy; Treatment patterns

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; TREATMENT DURATION; CANCER GRADING; HISTORY; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84951818709     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.09.002     Document Type: Article

References (37)

1. [1] Bolla, M., Gonzalez, D., Warde, P., Dubois, J.B., Mirimanoff, R.O., Storme, G., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997), 295–300.
2. [2] Logothetis, C., Millikan, R., Update: NCCN Practice Guidelines for the treatment of prostate cancer. Oncology 13 (1999), 118–132.
3. [3] Bill-Axelson, A., Holmberg, L., Ruutu, M., Haggman, M., Andersson, S.O., Bratell, S., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005), 1977–1984.
4. [4] Pierorazio, P.M., Ross, A.E., Schaeffer, E.M., Epstein, J.I., Han, M., Walsh, P.C., et al. A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy. J Urol 185 (2011), 1691–1697.
5. [5] Secin, F.P., Bianco, F.J. Jr., Vickers, A.J., Reuter, V., Wheeler, T., Fearn, P.A., et al. Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy. Cancer 106 (2006), 2369–2375.
6. [6] Sofer, M., Savoie, M., Kim, S.S., Civantos, F., Soloway, M.S., Biochemical and pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle invasion. J Urol 169 (2003), 153–156.
7. [7] Surveillance, Epidemiology, and End Results (SEER) Program (Available at: www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2013 Sub (1973–2011 varying)—Linked To County Attributes—Total U.S., 1969–2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014 (updated 5/7/2014), based on the November 2013 submission.
8. [8] Furlow, B., US National Cancer Institute investigates PSA coding errors. Lancet Oncol, 16, 2015, 614.
9. [9] Akre O. U.S. National Institutes of Health: Surgery versus radiotherapy for locally advanced prostate cancer (SPCG-15). 2014. Retrieved from: http://clinicaltrials.gov (Identification No. NCT02102477).
10. [10] Mohler, J., Bahnson, R.R., NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw, 2, 2008, 2008.
11. [11] Berglund, R.K., Jones, J.S., Ulchaker, J.C., Fergany, A., Gill, I., Kaouk, J., et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology 67 (2006), 1253–1256.
12. [12] Gontero, P., Marchioro, G., Pisani, R., Zaramella, S., Sogni, F., Kocjancic, E., et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol 51 (2007), 922–929 [discussion 9–30].
13. [13] Loeb, S., Schaeffer, E.M., Trock, B.J., Epstein, J.I., Humphreys, E.B., Walsh, P.C., What are the outcomes of radical prostatectomy for high-risk prostate cancer?. Urology 76 (2010), 710–714.
14. [14] Hsu, C.Y., Joniau, S., Oyen, R., Roskams, T., Van Poppel, H., Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 51 (2007), 121–128 [discussion 8–9].
15. [15] Yossepowitch, O., Eggener, S.E., Serio, A.M., Carver, B.S., Bianco, F.J. Jr., Scardino, P.T., et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 53 (2008), 950–959.
16. [16] Pierorazio, P.M., Guzzo, T.J., Han, M., Bivalacqua, T.J., Epstein, J.I., Schaeffer, E.M., et al. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology 76 (2010), 715–721.
17. [17] Joniau, S., Hsu, C.Y., Lerut, E., Van Baelen, A., Haustermans, K., Roskams, T., et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 51 (2007), 388–394 [discussion 95–6].
18. [18] Ward, J.F., Slezak, J.M., Blute, M.L., Bergstralh, E.J., Zincke, H., Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95 (2005), 751–756.
19. [19] Freedland, S.J., Partin, A.W., Humphreys, E.B., Mangold, L.A., Walsh, P.C., Radical prostatectomy for clinical stage T3a disease. Cancer 109 (2007), 1273–1278.
20. [20] Mitchell, C.R., Boorjian, S.A., Umbreit, E.C., Rangel, L.J., Carlson, R.E., Karnes, R.J., 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int 110 (2012), 1709–1713.
21. [21] Stewart, S.B., Boorjian, S.A., Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urol Oncol 33 (2014), 235–244.
22. [22] Van Poppel, H., Joniau, S., An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 53 (2008), 253–259.
23. [23] Wiegel, T., Bottke, D., Steiner, U., Siegmann, A., Golz, R., Storkel, S., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27 (2009), 2924–2930.
24. [24] Thompson, I.M. Jr., Tangen, C.M., Paradelo, J., Lucia, M.S., Miller, G., Troyer, D., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. J Am Med Assoc 296 (2006), 2329–2335.
25. [25] Bolla, M., van Poppel, H., Collette, L., van Cangh, P., Vekemans, K., Da Pozzo, L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005), 572–578.
26. [26] Trock, B.J., Han, M., Freedland, S.J., Humphreys, E.B., DeWeese, T.L., Partin, A.W., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. J Am Med Assoc 299 (2008), 2760–2769.
27. [27] Widmark, A., Klepp, O., Solberg, A., Damber, J.E., Angelsen, A., Fransson, P., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373 (2009), 301–308.
28. [28] Warde, P., Mason, M., Ding, K., Kirkbride, P., Brundage, M., Cowan, R., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378 (2011), 2104–2111.
29. [29] Stone, N.N., Stock, R.G., Cesaretti, J.A., Unger, P., Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 76 (2010), 355–360.
30. [30] Wilt, T.J., Brawer, M.K., Jones, K.M., Barry, M.J., Aronson, W.J., Fox, S., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367 (2012), 203–213.
31. [31] Pierorazio, P.M., Ross, A.E., Lin, B.M., Epstein, J.I., Han, M., Walsh, P.C., et al. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int 110 (2012), 1122–1128.
32. [32] Sundi, D., Wang, V.M., Pierorazio, P.M., Han, M., Bivalacqua, T.J., Ball, M.W., et al. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis 17 (2014), 57–63.
33. [33] Williams, S.B., Prado, K., Hu, J.C., Economics of robotic surgery: does it make sense and for whom?. Urol Clin North Am 41 (2014), 591–596.
34. [34] Hakimi, A.A., Feder, M., Ghavamian, R., Minimally invasive approaches to prostate cancer: a review of the current literature. Urol J 4 (2007), 130–137.
35. [35] Mohler JL, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2015;1:2015.
36. [36] Bratt, O., Folkvaljon, Y., Hjalm-Eriksson, M., Akre, O., Carlsson, S., Drevin, L., et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol 68 (2015), 53–58.
37. [37] Underwood, W., De Monner, S., Ubel, P., Fagerlin, A., Sanda, M.G., Wei, J.T., Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol 171 (2004), 1504–1507.